Bivalirudin versus unfractionated heparin for prevention of hemofilter occlusion during continuous renal replacement therapy

Pharmacotherapy

Volumn 30, Issue 11, 2010, Pages 1117-1126

  Kiser, Tyree H ^a   MacLaren, Robert ^a   Fish, Douglas N ^a   Hassell, Kathryn L ^b   Teitelbaum, Isaac ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Bivalirudin; Bleeding; Continuous renal replacement therapy; Continuous venovenous hemofiltration; CRRT; CVVH; Dialysis; Direct thrombin inhibitor; Hemofilter; Hirulog; Thrombus

Indexed keywords

ANTITHROMBIN; HEPARIN; HIRULOG;

ACUTE KIDNEY FAILURE; ADULT; APACHE; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMOFILTRATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG HEMORRHAGE; MALE; OCCLUSION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANTICOAGULANTS; ANTITHROMBINS; CRITICAL ILLNESS; DOUBLE-BLIND METHOD; FEMALE; HEMOFILTRATION; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 78149350460     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.11.1117     Document Type: Article

References (44)

1. Guerin C, Girard R, Selli JM, Perdrix JP, Ayzac L, for the Rhone-Alpes Area Study Group on Acute Renal Failure. Initial versus delayed acute renal failure in the intensive care unit. A multicenter prospective epidemiological study. Am J Respir Crit Care Med 2000;161:872-9.
2. Stefanidis I, Frank D, Maurin N. Hemostasis activation markers in acute renal failure. Renal Fail 1998;20:147-55. (Pubitemid 28087841)
3. Cardigan RA, McGloin H, Mackie IJ, Machin SJ, Singer M. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Kidney Int 1999;55:1568-74. (Pubitemid 29157158)
4. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis 1997;30:S20-7.
5. Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 2007;11:218.
6. van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7:145-50.
7. Leslie GD, Jacobs IG, Clarke GM. Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration. Intensive Care Med 1996;22:1261-4.
8. Reeves JH, Cumming AR, Gallagher L, O'Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999;27:2224-8. (Pubitemid 29508342)
9. 1 and unfractionated heparin during continuous venovenous hemofiltration. Crit Care Med 1998;26:1208-12.
10. Lindhoff-Last E, Betz C, Bauersachs R. Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients. Clin Appl Thromb Hemost 2001;7:300-4. (Pubitemid 32988894)
11. de Pont AC, Bouman CS, de Jonge E, Vroom MB, Buller HR, Levi M. Treatment with recombinant human activated protein C obviates additional anticoagulation during continuous venovenous hemofiltration in patients with severe sepsis. Intensive Care Med 2003;29:1205.
12. Tang IY, Cox DS, Patel K, et al. Argatroban and renal replacement therapy in patients with heparin-induced thrombocytopenia. Ann Pharmacother 2005;39:231-6.
13. Dager WE, White RH. Argatroban for heparin-induced thrombocytopenia in hepato-renal failure and CVVHD. Ann Pharmacother 2003;37:1232-6.
14. Hein OV, von Heymann C, Lipps M, et al. Hirudin versus heparin for anticoagulation in continuous renal replacement therapy. Intensive Care Med 2001;27:673-9.
15. Hein OV, von Heymann C, Diehl T, et al. Intermittent hirudin versus continuous heparin for anticoagulation in continuous renal replacement therapy. Renal Fail 2004;26:297-303. (Pubitemid 39050672)
16. Hofmann RM, Maloney C, Ward DM, Becker BN. A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF). Renal Fail 2002;24:325-35.
17. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006;32:188-202.
18. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and standardization committee communications on behalf of the control of anticoagulation subcommittee of the scientific and standardization committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost 2002;87:163-4. (Pubitemid 34092592)
19. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94.
20. Bastien O, French P, Paulus S, et al. Antithrombin III deficiency during continuous venovenous hemodialysis. Contrib Nephrol 1995;116:154-8.
21. du Cheyron D, Bouchet B, Bruel C, Daubin C, Ramakers M, Charbonneau P. Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study. Crit Care 2006;10:R45.
22. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000;96:1703-8. (Pubitemid 30661052)
23. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy 2006;26:452-60.
24. Mueller SW, MacLaren R, Fish DN, Kiser TH. Prefilter bivalirudin for preventing hemofilter occlusion in continuous renal replacement therapy. Ann Pharmacother 2009;43:1360-5.
25. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. Crit Care 2004;8:R204-12.
26. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004;30:260-5. (Pubitemid 38253417)
27. Joannidis M, Kountchev J, Rauchenzauner M, et al. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Med 2007;33:1571-9. (Pubitemid 47312476)
28. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005;67:2361-7. (Pubitemid 41623398)
29. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000;26:1652-7.
30. Kostering H, Girndt J, Matthaei D, Naidu R, Quellhorst E. Alterations of clotting factors and platelets during hemofiltration. J Dial 1977;1:607-17.
31. Napolitano LM, Warkentin TE, Almahameed A, Nasraway SA. Heparin-induced thrombocytopenia in the critical care setting: diagnosis and management. Crit Care Med 2006;34:2898-911.
32. Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 2000;35:802-11.
33. Munjal S, Ejaz AA. Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations. Nephrology (Carlton) 2006;11:405-9.
34. Gabutti L, Marone C, Colucci G, Duchini F, Schonholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med 2002;28:1419-25.
35. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009;37:545-52.
36. Wilson RF, Farag A, Mammen EF, Fujii Y. Sepsis and antithrombin III, prekallikrein, and fibronectin levels in surgical patients. Am Surg 1989;55:450-6.
37. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998;24:19-25.
38. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998;24:663-72.
39. Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000;70:873-7.
40. Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen SL. Heparin clearance during continuous veno-venous haemofiltration. Intensive Care Med 1994;20:212-15.
41. Spiess BD, DeAnda A, McCarthy HL, et al. Case 1-2006: off-pump coronary artery bypass graft surgery anticoagulation with bivalirudin: a patient with heparin-induced thrombocytopenia syndrome type II and renal failure. J Cardiothorac Vasc Anesth 2006;20:106-11.
42. Roguin A, Steinberg BA, Watkins SP, Resar JR. Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function. Int J Cardiovasc Intervent 2005;7:88-92.
43. Kiser TH, Burch JC, Klem PM, Hassell KL. Safety, efficacy, and dosing requirements of bivalirudin in patients with heparin-induced thrombocytopenia. Pharmacotherapy 2008;28:1115-24.
44. Ndrepepa G, Schulz S, Keta D, et al. Bleeding after percutaneous coronary intervention with bivalirudin or unfractionated heparin and one-year mortality. Am J Cardiol 2010;105:163-7.